REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026 UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025 REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pending FDAFDA advisory committee meetings scheduled: late July 2026 RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026 UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025 REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pending FDAFDA advisory committee meetings scheduled: late July 2026 RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Gabrielle Lyon

Influencer

Gabrielle Lyon

Videos

Your Doctor Is Watching the Wrong Number. LDL, ApoB & Heart Risk Explained. - Dr. Kevin Maki | #207

The lie women were told about lifting

This is the Single most overlooked Investment

Why women are afraid of lifting weights

The Real Reason You Can't Stay Consistent With Your Health Habits

Why HRT Alone Won't Fix Your Belly Fat - Dr. Michelle Pearlman

The most important organ you are ignoring!

Your Doctor Says You're Too Young for This Cancer

The Cancer Doctors Keep Missing in Young Adults - Dr. Michelle Pearlman | DLS #206

When Your Kid Understands Fitness Better Than You Do